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Abstract
Clinical, epidemiological, and genetic evidence suggest overlapping pathogenic mechanisms between autism spectrum
disorder (ASD) and schizophrenia. We tested this hypothesis by asking if mutations in the ASD gene MECP2 which cause Rett
syndrome affect the expression of genes encoding the schizophrenia risk factor dysbindin, a subunit of the biogenesis of
lysosome-related organelles complex-1 (BLOC-1), and associated interacting proteins. We measured mRNA and protein
levels of key components of a dysbindin interaction network by, quantitative real time PCR and quantitative
immunohistochemistry in hippocampal samples of wild-type and Mecp2 mutant mice. In addition, we confirmed results
by performing immunohistochemistry of normal human hippocampus and quantitative qRT-PCR of human inducible
pluripotent stem cells (iPSCs)-derived human neurons from Rett syndrome patients. We defined the distribution of the
BLOC-1 subunit pallidin in human and mouse hippocampus and contrasted this distribution with that of symptomatic
Mecp2 mutant mice. Neurons from mutant mice and Rett syndrome patients displayed selectively reduced levels of pallidin
transcript. Pallidin immunoreactivity decreased in the hippocampus of symptomatic Mecp2 mutant mice, a feature most
prominent at asymmetric synapses as determined by immunoelectron microcopy. Pallidin immunoreactivity decreased
concomitantly with reduced BDNF content in the hippocampus of Mecp2 mice. Similarly, BDNF content was reduced in the
hippocampus of BLOC-1 deficient mice suggesting that genetic defects in BLOC-1 are upstream of the BDNF phenotype in
Mecp2 deficient mice. Our results demonstrate that the ASD-related gene Mecp2 regulates the expression of components
belonging to the dysbindin interactome and these molecular differences may contribute to synaptic phenotypes that
characterize Mecp2 deficiencies and ASD.
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Introduction
Autism spectrum disorder (ASD) and schizophrenia are
disorders with some intersecting clinical characteristics such as
their shared impairment of social cognition [1–4]. Phenotypic
similarities between these disorders suggest common molecular
roots [5]. This hypothesis has recently received substantial support
from epidemiological, bioinformatic, and genetic studies [6].
Epidemiological evidence points to non-genetic and genetic risk
factors. Among the non-genetic factors, obstetric complications as
well as migrant status increase the risk of both schizophrenia and
autism [7] while among genetic risk factors a parental history of
schizophrenia increases the risk for ASD and advanced paternal
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e65069
age is a risk factor for both schizophrenia and ASD [8–10].
Advanced paternal age can be explained by the increased rate of de
novo mutations during spermatogenesis in older subjects [9].
Genome-wide association studies further support common molec-
ular roots between schizophrenia and ASD. An increasing number
of copy number variations that span multiple genes associate with
both schizophrenia and ASD [11,12]. This supportive genetic
evidence extends to monogenic defects such as those in GPHN
[13], ANK3 [14], NRXN1 or MECP2. NRXN1 encodes a
presynaptic neuronal cell adhesion molecule [15,16] and NRXN1
genetic defects robustly associate with schizophrenia and ASD
[17–21]. Similarly, mutations in the X-linked MECP2 gene, which
encodes the transcriptional regulator methyl-CpG-binding protein
2 (MeCP2), result in one of the ASDs, the Rett syndrome, and are
associated with childhood schizophrenia [22–26]. Genetic manip-
ulation of Mecp2 in mice causes well-characterized synaptic
phenotypes and a transcriptional signature, which is defined from
mRNA expression profiles in loss- and gain-of-function mouse
mutations [22,27]. Mutations to Mecp2 affect the neuronal
expression of 12–15% of the mouse genome [28,29], suggesting
that some of these MeCP2-regulated transcripts could encode
unrecognized synaptic proteins associated with schizophrenia
pathogenesis. Here, we focus on a MeCP2-dependent mechanism
that regulates the expression of subunits of the biogenesis of
lysosome related organelles complex 1 (BLOC-1), a synaptic
complex that contains the schizophrenia-associated protein,
dysbindin.
Dysbindin and its protein interaction network regulate mech-
anisms implicated in schizophrenia pathogenesis pathways.
Polymorphisms in DTNBP1, the gene encoding dysbindin,
associate with schizophrenia [30–32]. Moreover, a significant
reduction of synaptic dysbindin expression has been reported in
nearly 80% of schizophrenia cases [33–36]. Dysbindin is part of a
protein interaction network spanning a minimum of 24 experi-
mentally identified proteins. Nearly one-third of the genes
encoding these dysbindin network components are affected by
copy number variation defects in schizophrenia subjects [37].
Functions ascribed to dysbindin further support its participation in
schizophrenia disease mechanisms. Dysbindin is part of the
octameric protein complex BLOC-1, which is involved in the
targeting of membrane proteins from endosomes to diverse
organelles and the synapse [31,32,38,39]. Dysbindin localizes to
pre- and post-synaptic compartments. At the pre-synaptic level, its
deficiency affects synaptic homeostasis, synaptic vesicle composi-
tion and vesicle fusion, while at the post-synaptic level, its
deficiency alters the surface content of glutamatergic and
dopaminergic receptors, which are strongly implicated in schizo-
phrenia pathogenesis [40–49]. The synaptic mechanisms in which
the dysbindin network participates as well as the experimentally
verified nature of this protein-protein interaction network make it
a good target for exploring mechanistic convergence between ASD
and schizophrenia. Here we test this idea by investigating if
MeCP2 regulates the expression of components of the dysbindin
protein interaction network. To this end, we first defined the
normal anatomical and ultrastructural distribution of the BLOC-1
subunit pallidin in human and mouse hippocampus. Next, we
demonstrate that Mecp2 mice (Mecp2tm1.1.Jae/y) expressing a non-
functional truncated protein possess reduced levels of pallidin
transcript and synaptic protein expression in the hippocampal
formation. Moreover, we recapitulated this reduced pallidin
mRNA phenotype in human iPSCs differentiated into neurons
from Rett syndrome patients carrying mutations in MECP2. The
impaired pallidin expression phenotype in Mecp2 mutant mice is
most prominent at asymmetric synapses. We determined that
Mecp2 and BLOC-1 deficiencies share a reduced content of brain-
derived neurotrophic factor (BDNF), suggesting that BLOC-1 is
upstream of the BDNF phenotype in MeCP2-deficient brain.
These findings reveal a novel molecular link between an ASD
causative gene, Mecp2, and the protein interactome of the
schizophrenia susceptibility gene product, dysbindin. We speculate
that defects on the dysbindin interactome may contribute to
synaptic and circuit defects that characterize Mecp2 mutations.
Materials and Methods
Reagents
Mouse-anti pallidin was a gift from Dr. Esteban Dell’Angelica
(UCLA, Los Angeles, California) [50] and rabbit anti-VAMP-2
was purchased from Synaptic Systems (Go¨ttingen, Germany).
Synaptophysin (SY38) antibody was from Chemicon Internation-
al/Millipore (Billerica, MA, USA). Rabbit polyclonal antibodies
against BDNF were from Santa Cruz (Dallas, Texas. SC-5456)
and human recombinant BDNF was from Promega (Madison, WI.
G1491). The monoclonal antibody specificity in brain immuno-
histochemistry was determined in this study using pallidin-null
Bloc1s6pa/pa brain. B6.Cgpa/J breeding pairs were obtained from
Jackson Labs (Bar Harbor, Maine). Breeding pairs of Mecp2 mice
[51] were purchased from the Mutant Mouse Regional Resource
Center at the University of California, Davis (B6.Cg-Mecp2tm1.1Jae,
‘‘Jaenisch’’ strain maintained in C57BL/6 background), and a
colony established at UAB. Mice were bred in-house following
Emory and UAB IUCAC approved protocols.
Quantitative Real Time PCR (qRT-PCR)
Control and mutant cortical and hippocampal regions were
dissected from P7 animals, which are asymptomatic, and young
adult animals between P42–P52 sacrificed by CO2 narcosis.
Tissue was then flash frozen. Following TRIzol (Invitrogen Life
Technologies, Grand Island, NY) extraction, isolated mRNA was
reverse transcribed into cDNA using SuperScript III First-Strand
Synthesis (Invitrogen Life Technologies, Grand Island, NY). PCR
amplifications were performed on a LightCycler480 Real Time
plate reader using LightCycler 480 SYBR Green reagents (Roche,
Indianapolis, IN). Table 1 describes the primers used in this study.
Brain Sections, Immunohistochemistry and Microscopy
Detailed procedures for mouse tissue preparation, immunoper-
oxidase light microscopy, indirect immunofluorescence microsco-
py, immunoperoxidase electron microscopy and quantification
procedures were described in our previous work [37,43,44].
Briefly, brain slice preparations were obtained from mice
between 6 to 8 weeks of age. Following deep anesthesia with
ketamine, animals were transcardially perfused with Ringer’s
solution followed by fixative (4% paraformaldehyde with 0.1%
glutaraldehyde). Following postfixation, their brains were cut into
60 mm thick sections and processed to localize pallidin at the light
and electron microscopic level using mouse anti-Pallidin antibod-
ies (1:400), the peroxidase-anti-peroxidase (PAP) method and 3,39
diaminobenzidine (DAB) as chromogen for the peroxidase
reaction, according to procedures described in detail in our recent
studies [37,43,44].
For light microscopy, sections were mounted on gelatin-coated
slides, dehydrated, and coverslipped. Light microscopy analysis
was performed with a Leica DMRB microscope (Leica Micro-
systems, Inc., Bannockburn, IL, USA) and images were captured
with a CCD camera (Leica DC500). Images were acquired with a
10x/0.3 DiC objective. Images were acquired with Leica IM50
software.
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Electron microscopy sections were further postfixed in osmium
tetroxide, dehydrated and embedded in resin on microscope slides
according to procedures described in our recent studies [37,43,44].
From this EM-prepared tissue, blocks of the dentate gyrus were
mounted on resin blocks, faced with a glass knife, and sectioned
with a diamond knife into 60 nm sections with an ultramicrotome
(Leica Ultracut T2). Sections were collected on Pioloform-coated
copper grids and stained with lead citrate for 5 minutes to enhance
contrast on the electron microscope. Electron microscopy was
performed with a Zeiss EM-10C and a JEOLL electron
microscopes equipped with CCD cameras (DualView 300 W;
Gatan, Inc., Pleasanton, CA, USA). Images were acquired with
Gatan Digital Micrograph Software (v. 3.10.1; Gatan, Inc.)
Ultrathin sections from the surface of the blocks of the dentate
gyrus corresponding to regions where the neuropil and cell bodies
intersect were chosen. Random fields of view including asymmet-
ric synapses were imaged at 30 000–50 000X. A total of 25 fields
were examined in each animal or a total of 70–100 fields was
analyzed per genotype. The proportion of terminals with pallidin-
immunoreactive active zones and spines with labeled PSDs was
estimated in control and mutant mice.
The human hippocampus tissue was obtained from non-
psychiatric individuals. Human hippocampus data is representa-
tive data from 19 normal human cases (9 males, 10 females)
studied. The mean age +/2 the SD was 81.11+/29.8 years. The
mean postmortem interval (PMI) +/2 the SD was 11.34+/29.2
hours. After removal of the hippocampal formation, the tissue was
fixed for 12–24 hours in either neutral buffered formalin or
ethanol in saline. Following embedding in paraffin, the tissue was
sectioned at 10 mm, mounted on adhesive-coated slides, air dried,
and then processed immunohistochemically for pallidin using a
monoclonal antibody described above (1:150), heat-induced
epitope retrieval with EDTA, and a standard avidin-biotin
peroxidase with light silver intensification following the protocol
of Talbot et al. (2004) [33].
Immunofluorescence Microscopy
Confocal microscopy was performed with an Axiovert 100 M
microcope (Carl Zeiss) coupled to an Argon and HeNe1 lasers.
Images were acquired using Plan Apochromat 10x/0.5 dry, 206/
0.5 dry, and 406/1.3 and 636/1.4 DiC oil objectives. Emission
filters used for fluorescence imaging were BP 505–530 and LP 560.
Images were acquired with ZEN and LSM 510 software (Carl
Zeiss). Hippocampal formation 60 mm-thick brain sections were
rinsed with PBS and then incubated in 1% sodium borohydride in
PBS for 20 minutes at room temperature. Samples were pre-
incubated in a solution of PBS with 5% normal horse serum and
1% BSA and 0.3% Triton X-100 for 60 minutes at room
temperature. Samples were incubated overnight at 4uC in primary
antibody solutions of PBS with 1% NHS and 1% BSA. After
rinsing in PBS, sections were incubated for 60 minutes in a
secondary antibody PBS solution with 1% NHS and 1% BSA and
1:500 dilutions of the following Alexa-conjugated secondary
antibodies: anti-mouse 555 and anti-rabbit 488 (Invitrogen
Molecular Probes, Carlsbad, CA, USA). Following PBS rinses,
sections were incubated in cupric sulfate (3.854 W/V Ammonium
Acetate, 1.596 W/V Cupric Sulfate in distilled water, pH 5) for 30
minutes and mounted on slides with Vectashield (Vector
Laboratories).
Light Microscopy Quantitations
Quantitations of peroxidase light microscopy staining and
immunofluorescence were performed as previously described
using Metamorph software [43–45].
Human iPSCs Cells and Neuronal Differentiation
The monoallelic expressing Rett syndrome iPSCs cells RTT3
and RTT4 were previously characterized [52]. iPSCs cells were
differentiated into neural rosettes and neurons as described by Li
and Zhang [53]. Neurons were generated from these cells by
interference with bone morphogenetic protein signaling [54].
Mouse and Human Subjects
Animal Procedures were approved by the IACUC committee at
Emory University and the University of Alabama. Data on human
postmortem tissue derived from samples of U.S. citizens autopsied
at the Hospital of the University of Pennsylvania as approved by
the Institutional Review Board at that university. Autopsy consent
from next-of-kin or legal guardian was obtained in all cases. For
most cases, consent was granted in writing before death and
always confirmed after death. Ethics committee at the University
of Pennsylvania approved consent procedures. To keep postmor-
tem delays to a minimum when written consent had not been
obtained before death, verbal consent was obtained as witnessed
by a third party and documented by the physician making the
request. Written records of the consent for autopsy were archived.
These procedures for written and verbal consent are standard
medical practice in the U.S.A.
Statistical and Bioinformatic Analyses
Statistical analyses were performed with Synergy KaleidaGraph
v4.03 (Reading, PA) or the Vassar Web Engine (http://vassarstats.
net/). BLOC-1 interacting proteins were compiled from our
quantitative dysbindin interactome and a previously published
curated list of putative candidate interactors [37,55]. A BLOC-1
network interaction map was built using GeneGo Metacore
(version 6.11 build 41105) and visualized in Cytoscape (version
2.8.3). Node color and sizes were mapped to changes in mRNA
expression level in MECP2-overexpressing and Mecp2–null mouse
neuronal cells as previously reported [29].
Results
Bioinformatic Analysis Identify BLOC-1 Components
among MeCP2-regulated Transcripts
The similarities between ASD and schizophrenia could result
from a gene product affected in ASD. Such a gene could in turn
modify the expression of proteins associated with pathways
implicated in schizophrenia. We tested this hypothesis by
investigating if the expression of genes encoding components of
the dysbindin protein interaction network is susceptible to MeCP2
levels. We built a comprehensive dysbindin network by merging
our dysbindin protein interaction network of 24 candidates with a
prioritized list of putative protein-protein interactions for BLOC-1
subunits [37,55]. The resultant dysbindin network contained 119
proteins. Six of these dysbindin interactome components were
common to gene products whose mRNA expression is sensitive to
Mecp2 content as previously determined by microarrays (Fig. 1)
[29]. Pallidin (Pldn), peroxiredoxin 1 (Prdx1), COG7, pleiotrophin
(PTN), ADP-ribosylation factor interacting protein 2 (ARFIP2),
huntingtin-associated protein 1 (HAP1), and discoidin domain
receptor tyrosine kinase 1 (DDR1) mRNAs are increased in
MECP2 over-expressing mouse neurons (Fig. 1A, Mecp2Tg/y) and
decreased in Mecp2-null mouse neurons (Fig. 1B, Mecp22/y). We
previously demonstrated that three of these six proteins, pallidin,
peroxiredoxin 1, and COG7, interact with dysbindin and their
brain expression is sensitive to a dysbindin-null allele (Bloc1s8sdy/sdy
previously referred as Dtnbp1sdy/sdy) [37]. Our bioinformatic
MeCP2 Regulates the Synaptic Expression of BLOC-1
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e65069
analysis suggests that MeCP2 regulates expression of key
components of the dysbindin interaction network.
We used quantitative real time PCR to determine the mRNA
levels of transcripts encoding dysbindin and other BLOC-1
subunits in samples from the hippocampus and cortex from
symptomatic young adult Mecp2tm1.1Jae/y mice and littermate
controls. The mRNA levels of pallidin decreased by 26% in the
hippocampus of symptomatic Mecp2tm1.1Jae/y mice as compared to
controls (p,0.002 Mann-Whitney U test). In contrast, Bloc1s1–3,
dysbindin, and muted transcripts were not affected in Mecp2tm1.1-
Jae/y hippocampus. The reduced content of pallidin was restricted
to the hippocampus since all BLOC-1 subunit transcripts
remained unaffected in Mecp2tm1.1Jae/y cortex (Fig. 2A). Since Rett
syndrome affects the brain during development, we explored if
BLOC-1 subunit mRNA levels were susceptible to Mecp2
deficiency before becoming symptomatic [56,57]. We examined
Figure 1. MeCP2 Regulates mRNA Levels of BLOC1-Interacting Proteins. BLOC1-interacting proteins were compiled from previous reports
and mapped using the GeneGo Metacore pathway. The network was visualized in Cytoscope. Node sizes and colors were mapped to mRNA
expression level changes in MECP2-overexpressing (A, Mecp2Tg/y) and Mecp2 null mouse (B, Mecp22/y) neurons as reported in Chahrour et al., 2008
[29]. We observed that six components of the BLOC1 interactome were modified by Mecp2 gene dosage. The protein products of three of these
affected genes, PLDN, COG7, and PRDX1, are decreased in mice null for the schizophrenia susceptibility factor dysbindin [37].
doi:10.1371/journal.pone.0065069.g001
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mice at postnatal day seven, P7, a period that coincides with
enhanced hippocampal synaptogenesis [58] and when alterations
in spine formation occur in the Mecp2 mutant mice [59]. The
BLOC-1 pallidin subunit transcript was 50.5% lower in
Mecp2tm1.1Jae/y P7 hippocampi, a statistically significant decrease.
Mouse mutants carrying one copy of a null allele of pallidin
(Bloc1s6+/pa) showed a 50% reduction of pallidin mRNA (data not
shown), indicating that the effect of Mecp2-mutant upon pallidin
mRNA expression is equivalent to the loss of one copy of the gene
encoding pallidin. Strikingly, muted mRNA was also diminished in
Mecp2 mutant hippocampi (Fig. 2B, 70% of control, p,0.0004
Mann-Whitney U test). P7 cortical transcripts encoding BLOC-1
subunits were not affected by the Mecp2 mutant allele (Fig. 2B).
These data demonstrate that MeCP2 regulates the expression of
transcripts encoding BLOC-1 subunits in an anatomic and
temporal-specific manner.
Pallidin Transcript Content Decreases in Human MECP2-
deficient Neurons
We sought to determine if the pallidin mRNA phenotypes
observed in Mecp2tm1.1Jae/y mouse hippocampus were observed in
Rett syndrome human neural tissue. We took advantage of
neuronal cells differentiated from human iPSCs cells generated
from skin fibroblasts of Rett syndrome patients. Fibroblasts were
reprogramed into iPSCs by infecting them with a retrovirus
expressing OCT4, SOX2, KLF4, and MYC. MECP2 is encoded
in the X-chromosome, the status of which is maintained after
reprogramming (Fig. 3A) [60]. This chromosomal inactivation
allowed us to generate IPSC clones from the same patient where
either the wild-type or the MeCP2 mutant alleles were selectively
expressed [52]. This approach facilitates transcript expression
analysis since control and experimental samples are from the same
individual, thus eliminating contributions by inter-individual
genome differences [52].
We focused on patients carrying singleMECP2 alleles, E235fs or
the R306C, and generated monoallellic expressing iPSC lines that
we differentiated into neurons. We validated these cells by
recapitulating a neuronal maturation defect we have previously
reported [52]. This phenotype is characterized by a 50% decrease
in the neuronal specific markers NeuroD1 and the neuron specific
beta tubulin III, TuJ, encoded by TUBB3 (Fig. 3B). Pallidin
mRNA was significantly reduced by 35% in neurons mono-
allellically expressing mutant MeCP2 (Fig. 3B). However, the
mRNA levels of the BLOC-1 subunit, Bloc1s1, were not
significantly different compared to neurons expressing the wild
type allele of MECP2 or a control transcript (GFAP). These results
demonstrate that defects in the expression of pallidin mRNA
observed in Mecp2tm1.1Jae/y mice are common to those of patients
carrying two different mutant alleles of MECP2.
Anatomical Distribution of Mecp2 in Mouse and Human
Brain
In order to assess the consequences of a Mecp2 mutation upon
pallidin hippocampal protein expression, we first determined the
anatomical localization of pallidin, which has not been reported in
the mammalian brain. To this end, we used a monoclonal
antibody against pallidin in adult mouse and human hippocampal
tissue (Fig. 4) [61]. We established the specificity of this antibody in
tissue sections from wild-type and pallidin-null Bloc1s6pa/pa brain,
as demonstrated by the loss of immuno-peroxidase labeling in
pallidin-null brain (Fig. 4, compare A–B). We then examined the
distribution of pallidin in human hippocampal tissue. Strong
pallidin immunoreactivity was observed throughout the neuropil
of the human hippocampal formation (Fig. 4C, HF). Similar to the
distribution of dysbindin we previously reported [33], the highest
neuropil levels of pallidin were found in axon terminal fields of
glutamatergic neurons intrinsic to the hippocampal formation,
most conspicuously in the inner molecular layer of the dentate
gyrus (Fig. 4C, DGiml) and among CA2 and CA3 pyramidal cells
(Fig. 4C). Figures 4D–G also show that neurons producing these
axon terminal fields (hippocampal pyramidal cells in CA3 and
polymorph cells in the dentate gyrus hilus [DGh]) are also rich in
pallidin (Fig. 4 D, F), as are pyramidal cells in the subiculum
(Fig. 4E). Pallidin in dentate gyrus granule cells are clearly seen in
Fig. 4G. The distribution of pallidin in mouse brain was similar to
the human hippocampus, with a prominent staining in the
neuropil of the dentate gyrus hilus and synaptic fields such as the
molecular layer of the dentate gyrus (Fig. 4A and H).
Dysbindin is localized to presynaptic and postsynaptic com-
partments yet if other subunits of the BLOC-1 complex are
localized to the synapse remains unknown [40]. Immunofluores-
cence microscopy revealed the presence of pallidin concentrated in
cell bodies of dentate gyrus neurons and as a diffuse staining in the
adjacent neuropil (Fig. 4J–J9). A similar pattern was observed by
immuno-peroxidase staining (Fig. 4F). The low neuropil pallidin
signal attained precluded colocalization studies with a universal
presynaptic marker, the synaptic vesicle protein VAMP2 (Fig. 4J–
Figure 2. Quantitative Real Time PCR Determination of BLOC-1
Subunit Transcripts. BLOC-1 subunit transcripts from symptomatic
adult (A) and P7 (B) mice hippocampi and cortices were analyzed by
qRT-PCR. Box plot depicts relative mRNA content for wild type (Mecp2+/
y, Blue) and Mecp2 mutant tissue (Mecp2tm1.1Jae/y, Red). P values were
obtained by Mann-Whitney U test. Number of animals tested is
presented in Table 1.
doi:10.1371/journal.pone.0065069.g002
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J9) [62]. Thus to address the subcellular localization of pallidin, we
performed quantitative immuno-electron peroxidase microscopy
of the dentate gyrus and determined the ultrastructural distribu-
tion of pallidin in wild-type and pallidin-null Bloc1s6pa/pa hippo-
campal tissue. Pallidin immunoreactivity was present in axon
terminals, axons, and dendritic spines in the dentate gyrus of wild-
type animals (Figs. 5A–D, F–G, I–J). Pallidin immunoreactivity
decorated synaptic vesicles closely apposed to the active zone
(Fig. 5A–D), coated vesicles or cisternae present in dendritic spines
(CCV and Cist, respectively, Fig. 5C), and internal vesicles of
multivesicular bodies located in spines (MVB, Fig. 5F). None of
these structures were labeled in pallidin-null Bloc1s6pa/pa tissue
(Fig. 5, I–J). These results indicate that pallidin is present in pre-
and post-synaptic compartments consistent with a role of BLOC-1
and its protein interaction network modulating synaptic physiol-
ogy.
This anatomical and ultrastructural distribution of pallidin in
human and mouse hippocampus was contrasted between wild type
and Mecp2 mutant mouse tissue. Notably, we observed a marked
reduction of pallidin immunoreactivity in the dentate gyrus, CA1
Table 1. qRT-PCR Primers Used in this Study and Animals Tested.
Forward Reverse Adult Braina P7 Braina IPSCs Lines
Bloc1s1 AGCAGAACGAACGCAAGG TTGAGGTGATCCACCAACG 5:5:4:3 3:3:3:3
Bloc1s2 AATGGCCACATATTTGACTGG TTCATATTTTCCAGGAGTTTGTAGTC 5:5:5:3 3:3:3:3
Bloc1s3 GCCTAGGCTGTCACTCTGTGT GGTGGTACGAATGTTCACCA 4:4:3:3 3:3:3:3
Muted GAGAACAGGAACGGAAAAAGG TCCGCTCACGAACTCCTC 5:5:5:4 3:3:3:3
Pallidin CTCCAGACGGGGTCCTTAC AGTCCTTCATCTGGAGACGTG 5:5:5:4 3:3:3:3
SNAPIN CCGGATCAATGAGGATCAGA CCGCCTTAGTCGTTCCTGT 5:5:5:3 3:3:3:3
Dysbindin GATCGCAGAGAGGCGAGA TGAGATGTCCATCAGGTCCA 4:5:5:5 3:3:3:3
BDNF AGTCTCCAGGACAGCAAAGC TGCAACCGAAGTATGAAATAACC 4:4:
PLDN AACTCACACAGAACCAAGTTGT GGCATGATAGTGTTTAGCCTCAG 2
BLOC1S1 AGGAGGCGAGAGGCTATCAC GGACCTGTAGGGTCTTCACCT 2
TUBBS GCCGCTACCTGACGGTGGC GGGCGGGATGTCACACACGG 2
GFAP TGCTCGCCGCTCCTACGTCT ATCCACCCGGGTCGGGAGTG 2
NEUROD1 AGGTGGTGCCTTGCTATTCT TTGCAAAGCGTCTGAACGAA 2
aNumbers show IPSCs or animals analyzed in Figure 2, 3, 7 and correspond to Wild type hippocampus: Mecp2 or BLOC-1 mutant hippocampus: Wild type cortex: Mecp2
mutant cortex. Each animal qRT-PCR determination was performed at least in duplicate.
doi:10.1371/journal.pone.0065069.t001
Figure 3. Quantitative Real Time PCR Determination of Pallidin Transcripts in Neurons derived from Human IPSCs. (A) Experimental
design to generate monoallellic neurons from MECP2 mutant Rett syndrome patient cells. (B) Wild type and mutant monoallellic IPSCs from the same
patient were differentiated into neurons and analyzed by qRT-PCR. Plot depicts ratio of mRNA content between the wild type and mutant
monoallellic cells from the same subject (n = 2 patients). P values were obtained by One Way Anova with Dunnett’s Multiple comparisons correction.
doi:10.1371/journal.pone.0065069.g003
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and CA3 as well as their associated synaptic fields inMecp2tm1.1Jae/y
hippocampus (Fig. 4, compare H–I). We performed quantitative
confocal microscopy of the dentate gyrus labeled with antibodies
directed against pallidin and a control marker not affected by
BLOC-1 or Mecp2 mutant alleles, the synaptic vesicle protein
VAMP2 (VAMP2, Fig. 4 compare J–K) [43,62–64]. Similar to the
immuno-peroxidase results, pallidin content was reduced in the
dentate gyrus of Mecp2tm1.1Jae/y mice (Fig. 4, L) without affecting
the VAMP2 content (Fig. 4, M). We next asked if the reduction of
pallidin content affected the synapse. We quantified the number of
asymmetric synapses in wild type and symptomatic adult
Mecp2tm1.1Jae/y mice that were positive for pallidin immunoreac-
tivity by immunoelectron microscopy. Total synaptic counts per
unit area showed no significant difference between control and
Mecp2 or Bloc1s6 null genotypes (Fig. 5J). However, symptomatic
Mecp2tm1.1Jae/y mice demonstrated a 50% reduction in the number
of pallidin-positive presynaptic elements in asymmetric synapses of
the dentate gyrus (Fig. 5F–G compare to H, and I–J). Our results
Figure 4. Light Immunomicroscopy of Pallidin in Mouse Hippocampus. Images A, B, H-K’ depict sections from mouse hippocampus. Sections
correspond to immunoperoxidase microscopy with a pallidin monoclonal antibody in wild type (Bloc1s6+/+, A or Mecp2+/y, H), pallidin null (Bloc1s6pa/
pa, B) and Mecp2 mutant hippocampi (Mecp2tm1.1Jae/y, I). J–K’ depict indirect immunofluorescence microscopy of Pallidin and VAMP2. Quantitative
imaging was performed by confocal microscopy of wild type (Mecp2+/y, J–J9) and Mecp2 mutant hippocampus (Mecp2tm1.1Jae/y, K, K9). VAMP2 was
used as a control to normalize staining between animals and experiments. L–M) Box plots depict relative fluorescence intensity expressed as a ratio
between pallidin and VAMP2 and the total VAMP2 fluorescence intensity in the dentate gyrus, respectively. Wild type (Mecp2+/y, Blue, n = 4) and
Mecp2 mutant tissue (Mecp2tm1.1Jae/y, Red, n = 4) were analyzed. P values were obtained by Mann-Whitney U test. The VAMP2 content is similar
between genotypes. Scale bars A = 0.5 mm, H = 1 mm, J9= 25 mm. DGh, dentate gyrus hilus. Images C–G correspond to sections from human
hippocampal tissue stained with pallidin antibody. In C, HF denotes the hippocampal formation, consisting of the hippocampus proper (CA1–3), the
dentate gyrus (DG), and the subiculum (Sub). The inner molecular layer of the DG (C, DGiml), the DG hilus (DGh) and the dentat gyrus granule cells
layer (DGg) are indicated. Pallidin immunoreactivity is present in cell bodies of CA3 cells (D), subicular pyramidal cells (E), dentate gyrus hilus (F), and
dentate gyrus granule cells (G). The presence of pallidin in ectopic granule cells (arrow heads in G) verifies that granule cells, as opposed to terminal
fields among them, contain the protein. Note that pallidin is a cytoplasmic, not a nuclear protein. The scale bar in C is 1 mm; that in G is 50 mm.
doi:10.1371/journal.pone.0065069.g004
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show that pallidin protein expression phenotypes exceed those
predicted by the content of pallidin transcripts in adult
Mecp2tm1.1Jae/y hippocampus and demonstrate that MeCP2 regu-
lates the synaptic expression of a BLOC-1 network component.
Effects of Mecp2 and BLOC-1 Genetic Deficiencies on
BLOC-1 Cargo Content in the Dentate Gyrus
Reduced pallidin immunoreactivity in Mecp2tm1.1Jae/y dentate
gyrus suggests impaired BLOC-1-dependent trafficking in
Mecp2tm1.1Jae/y hippocampus. We and others have established that
BLOC-1 and its binding partner, the adaptor complex AP-3,
generate vesicles that target the SNARE VAMP7 and phospha-
tidylinositol-4-kinase type IIa (PI4KIIa) to nerve terminals [43–
45,65]. Mutations in BLOC-1 subunits lead to reduced AP-3,
PI4KIIa, and VAMP7 immunoreactivity in axons and/or
asymmetric axospinous nerve terminals in the dentate gyrus
[43,44,45]. Consistently, AP-3, VAMP7, and PI4KIIa are found
in synaptic vesicles [64,66,67]. Thus, we tested if Mecp2 mutations
would lead to reduced AP-3, PI4KIIa, and/or VAMP7 immuno-
reactivity in the dentate gyrus secondary to decreased pallidin
content. The immunoreactivity of PI4KIIa (Fig. 6A to 6B),
VAMP7 (Fig. 6C and C), and the delta subunit of AP-3 (AP-3d,
Fig. 6E and E), were not significantly modified in Mecp2tm1.1Jae/y
dentate gyrus. In contrast, VAMP7 immunoreactivity in dysbin-
din-null mice (Bloc1s8sdy/sdy, Fig. 6D–D) was robustly decreased in
Bloc1s8sdy/sdy, much like the phenotype previously observed in
BLOC-1 null mice Bloc1s6pa/pa or Bloc1s5mu/mu [44]. These results
Figure 5. Electron Immunomicroscopy of Pallidin in Mouse Dentate Gyrus. Images depict immunoperoxidase electron microscopy with a
pallidin monoclonal antibody in wild type (Bloc1s6+/+, A–D or Mecp2+/y, F–G), pallidin null (Bloc1s6pa/pa, E) and Mecp2 mutant hippocampi
(Mecp2tm1.1Jae/y, H). A–H depict representative asymmetric axospinous synapses from the hilus of the dentate gyrus. Sp, spine; MBV, multivesicular
body; CCV clathrin coated vesicle; Cist, cisterna. Structures were identified following defined ultrastructural criteria [88]. I) Box plot depicts
quantitation of pallidin immuno-positive synaptic compartments in wild type (Bloc1s6+/+ Mecp2+/y, Blue, n = 3), pallidin null (Bloc1s6pa/pa, Red, n = 1)
and Mecp2 mutant tissue (Mecp2tm1.1Jae/y, Red, n = 3). Dendrite includes immuno-positive spines as well as dendritic shafts. J) Synapse count and
numbers of pallidin immuno-positive synapses per genotype. Bars 200 nm.
doi:10.1371/journal.pone.0065069.g005
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suggest that genetic defects in Mecp2 do not affect the delivery of
BLOC-1 cargoes to synaptic vesicles.
Defective BLOC-1 function in Bloc1s8sdy/sdy mice results in
alterations in the structure and fusion of large dense secretory
granules [46]. Thus, we tested the hypothesis that neuropeptides
implicated in the pathogenesis of ASD and/or schizophrenia could
be commonly affected in Mecp2 and BLOC-1 genetic defects. We
focused on BDNF, a neurotrophic factor packaged in large dense
core vesicles present in pre- and post-synaptic terminals whose
content is reduced in diverse brain regions of Mecp2-deficient mice
[68–71]. We measured the immunoreactivity of BDNF and the
synaptic vesicle protein synaptophysin by quantitative confocal
immunofluorescence microscopy in dentate gyruses from
Mecp2tm1.1Jae/y, the BLOC-1-null mice Bloc1s8sdy/sdy, and Bloc1-
s6pa/pa (Fig. 7). BDNF antibody signal localized in the pre-synaptic
terminal as indicated by overlap with the synaptic vesicle marker
synaptophysin (Fig. 7A, Sphysin). BDNF immunoreactivity
specificity was confirmed by out-competition of the dentate gyrus
BDNF immunoreactivity with recombinant human BDNF
(Fig. 7A–B and in C compare blue and light blue boxes, rhBDNF).
Similar to previous reports, we also observed a pronounced
reduction of BDNF immunoreactivity in Mecp2tm1.1Jae/y dentate
gyrus (Fig. 7A–B and in C compare blue to red boxes) [68,71].
Importantly and analogous to Mecp2tm1.1Jae/y dentate gyrus, the
content of BDNF was reduced in the dentate of animals carrying
null alleles of the BLOC-1 complex, Bloc1s8sdy/sdy and Bloc1s6pa/pa
(Fig. 7A–B and in C compare blue to red boxes). These changes in
BDNF immunoreactivity in Mecp2 and BLOC-1 deficient dentate
gyrus were not due to changes in BDNF mRNA content as
determined by qRT-PCR (Fig. 7D compare blue to red boxes).
These results demonstrate that genetic defects in Mecp2 and
BLOC-1 protein function generate a common BDNF phenotype,
a growth factor packaged into large secretory granules present in
nerve terminals.
Discussion
Phenotypic overlap between ASD and schizophrenia is likely
rooted in shared molecular pathways between both disorders [5].
This concept is supported by recent epidemiological evidence
suggesting that parental history of schizophrenia is a risk factor for
ASD and advanced paternal age is a risk factor for both
schizophrenia and ASD [8–10,72]. Moreover, genetic data
reaffirm common molecular roots to both disorders either at the
copy number variations level [11] or the disease phenotypes
observed in monogenic defects [17–21,23,26]. Here we expand
the mechanisms that could explain similarities between these
disorders testing the idea that molecular phenotypes downstream
of an ASD monogenic defect would encompass synaptic gene
products associated with schizophrenia. Our results reveal a novel
Figure 6. Mecp2 Deficiency Does Not Affect the Content of BLOC-1 Sensitive Markers in the Dentate Gyrus. Images depict indirect
quantitative immunofluorescence microscopy of PI4KIIa and VAMP2 (A–B) or immunoperoxidase light microscopy of VAMP7 (C–D) or the AP-3 d
subunit (E). A–E italic letters represent mutant Mecp2 and BLOC-1 Bloc1s8sdy/sdy. F–H Box plots depict the quantitation of immunoreactivities of
antigens presented in A–E and A–E. P values were obtained by Mann-Whitney U test, n = 4 independent stainings from 2 animals per genotype.
doi:10.1371/journal.pone.0065069.g006
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regulatory pathway linking MeCP2, an epigenetic transcriptional
regulator and an ASD-Rett syndrome causative gene, with the
interactome of the schizophrenia susceptibility gene product
dysbindin. We demonstrate that a mutation in Mecp2 in mice
and humans alters pallidin hippocampus transcript levels and in
mouse, protein content at the synapse. The mRNA phenotype in
mice is more pronounced in asymptomatic postnatal day 7
animals, a time associated with synapse formation in hippocampal
ontogenesis [58]. These findings suggest that altered function of
pallidin and/or the dysbindin pathway could contribute to part of
the synaptic defects that characterize MeCP2 deficiencies in
asymptomatic and symptomatic stages of disease [27,63,73–75].
This hypothesis is consistent with the reported functions of BLOC-
1 complex subunits in neuronal cells. Pallidin- or dysbindin-
deficient neurons or neuroblastoma cells have impaired neurito-
genesis in vitro [76–78]. In addition, dysbindin-null neurons and
chromaffin cells have defective fusion of synaptic vesicles and large
dense core granules, respectively [46]. These cellular defects likely
contribute to impaired paired-pulse facilitation in dysbindin-null
neurons [79] and the defective synaptic scaling observed in
dysbindin- or snapin-deficient Drosophila synapses [41,42]. Strik-
ingly, MeCP2 regulates synaptic scaling, suggesting that BLOC-1
subunits may underlie part of the scaling phenotypes in Mecp2
mutant neurons [80].
Dysbindin localizes to pre- and post-synaptic compartments in
mammalian neurons, yet before our study there were no reports of
the subcellular localization of pallidin in mammalian brain [40].
Pallidin immunoreactivity is present in synaptic fields in human
and mouse hippocampus. This light microscopy observation is
confirmed by immunoelectron microscopy where we detect
pallidin on synaptic vesicles in terminals forming asymmetric
synapses of the dentate gyrus as well as on cisternae and
multivesicular bodies in dendritic spines. This ultrastructural
subcellular distribution confirms biochemical studies of BLOC-1
subunits co-purifying with synaptic vesicles and synaptosomes
[34,44,81]. Moreover, pallidin localization to MVBs supports the
role of BLOC-1 complexes controlling surface expression and
lysosomal delivery of post-synaptic receptors [48,82]. Mecp2
mutation decreases the mRNA levels of pallidin by 26% in the
hippocampus of symptomatic animals and by ,30% in iPSCs-
derived neurons from patients carrying MECP2 pathogenic
mutations. Pallidin protein immunoreactivity by light and electron
immunomicroscopy is even more reduced in the neuropil and cell
bodies of neurons in the dentate gyrus. This enhanced pallidin
reduction suggests additional factors downstream of MeCP2
control the protein expression of pallidin. The identity of such
mechanisms remains unknown. Immunoelectron microscopy
indicates that 70% of asymmetric axospinous synapses in the
Mecp2 mutant mice have no detectable pallidin in the dentate
gyrus. Other synaptic fields in the hippocampus such as the
stratum lucidum in CA3 also have decreased pallidin immunore-
activity, suggesting that the synaptic defect observed in the dentate
gyrus might be common to other synapses. The number of
synapses per unit area of the dentate gyrus is not affected inMecp2-
deficient mice as assessed by either ultrastructural synapse
counting or staining with the synaptic vesicle marker VAMP2
(Fig. 3–4). This result is similar to previous electron microscopy
findings in CA1 [57]. Thus, we interpret this decreased content of
pallidin-positive asymmetric axospinous synapses as decreased
expression of pallidin in synapses rather than decreased synapse
density. Importantly, loss of just one copy of dysbindin is sufficient
to trigger synaptic and behavioral phenotypes in mice [49,79],
supporting the contention that a 50% reduction in the levels of
pallidin observed by immunoelectron microscopy in Mecp2 mutant
Figure 7. Mecp2 and BLOC-1 Deficiency Affect BDNF Immunoreactivity in the Dentate Gyrus. Images depict indirect quantitative
immunofluorescence confocal microscopy of BDNF and the synaptic vesicle marker synaptophysin in the dentate gyrus from Mecp2tm1.1Jae/y, the
BLOC-1-null mice Bloc1s8sdy/sdy, and Bloc1s6pa/pa (A–B). BDNF immunorreactivity was abrogated by preincubation of antibodies with recombinant
human BDNF (rhBDNF, A–B). Box plots in C depict the quantitation of BDNF immunoreactivity normalized to synaptophysin. P values were obtained
by One Way Anova with Dunnett’s Multiple comparisons correction, n = 4 independent stainings from 2 animals per genotype. D, BDNF transcripts
from symptomatic adult mice hippocampi were analyzed by qRT-PCR. Box plot depicts relative mRNA content for wild type (Mecp2+/y, Blue), Mecp2
mutant tissue (Mecp2tm1.1Jae/y, Red), as well as the BLOC-1-null mice Bloc1s8sdy/sdy, and Bloc1s6pa/pa. P values were obtained by One Way Anova with
Dunnett’s Multiple comparisons correction, n = 4 animals per genotype.
doi:10.1371/journal.pone.0065069.g007
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hippocampus may contribute to synaptic and circuit defects that
characterize Mecp2 mutations [27,63,73–75].
The reduced pallidin immunoreactivity in Mecp2-deficient
hippocampus suggested that BLOC-1 sensitive cargoes delivered
to nerve terminals would be affected in the dentate gyrus of
Mecp2tm1.1Jae/y mice. We tested this hypothesis by analyzing the
expression of three proteins present in regulated secretory vesicles:
VAMP7 and PI4KIIa, which reside in synaptic vesicles and whose
targeting is dependent on BLOC-1 and AP-3 complexes, and
BDNF, which is present in large dense core granules [83–85]. We
focused on BDNF because its brain content is reduced in Mecp2
brains [68–71]. However, if brain BDNF is affected by BLOC-1
deficiency was unknown. Of these three secretory vesicle markers,
only BDNF immunoreactivity was reduced to the absence of
BLOC-1 in the dentate gyrus. In the past we have interpreted
reduced levels of an antigen in BLOC-1-null dentate gyrus as an
indication of defective membrane traffic [43]. However, our
findings with BDNF need additional evidence to determine if the
reduced BDNF immunoreactivity in the dentate gyrus is a
reflection of a BLOC-1-defective trafficking mechanism.
Mutations of dysbindin are associated with a destabilization of
other components of the BLOC-1 interactome [37,86,87]. For
example, dysbindin-null hippocampi possess reduced levels AP-3,
peroxiredoxin 1, and COG7 [37,43,44]. It is possible that MeCP2
deficiency may also influence other components of the BLOC-1
interactome as indicated in Fig. 1. In fact, the levels of muted are
reduced in Mecp2 deficient P7 hippocampi. We postulate that
diverse components of the BLOC-1 interactome may be targets for
transcriptional regulation by MeCP2 and/or may be directly
affected in de novo cases of ASD or other neurodevelopmental
disorders.
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